Table 2.
Univariate and multivariate analyses for death/liver transplantation and tumor recurrence in the ITT population.
| Death or liver transplantation | Tumor recurrence | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis* | Univariate analysis | Multivariate analysis* | |||||
| Factors | P | HR | 95% CI | P | P | HR | 95% CI | P |
| Age (≥60 vs. <60, years) | 0.157 | 0.649 | ||||||
| Sex (male/female) | 0.841 | 0.616 | ||||||
| HBV genotype (Type C/nontype C) | 0.982 | 0.213 | ||||||
| Increasing serum IFN-λ3 level at 3 months (Yes vs. No) | 0.783 | 0.132 | ||||||
| HBeAg (Positive vs. Negative) | 0.013 | 3.335 | 1.184–9.390 | 0.023 | 0.001 | 3.919 | 1.917–8.010 | <0.001 |
| HBV-DNA (≥2*10^3 vs. <2*10^3, IU/ml) | 0.025 | 0.026 | 2.411 | 1.145–5.074 | 0.020 | |||
| AFP (≥20 vs. <20, ng/ml) | 0.107 | 0.030 | 2.158 | 0.998–4.665 | 0.051 | |||
| TBIL (≥20 vs. <20, umol/l) | 0.835 | 0.093 | ||||||
| ALT (≥40 vs. <40, U/l) | 0.708 | 0.810 | ||||||
| ALB (<40 vs. ≥40, U/l) | 0.583 | 0.140 | ||||||
| CREA (≥90 vs. <90, mmol/l) | 0.364 | 0.269 | ||||||
| Differentiation (Moderate or Low vs. High) | 0.400 | 0.013 | ||||||
| Tumor number (Multiple vs. Single) | 0.004 | 4.699 | 1.691–13.055 | 0.003 | 0.007 | 3.233 | 1.627–6.425 | 0.001 |
| Tumor diameter, cm (≥3 vs. <3) | 0.047 | 4.317 | 1.278–14.588 | 0.019 | 0.037 | 2.315 | 1.144–4.684 | 0.020 |
| BCLC stage (A vs. 0) | 0.248 | 0.147 | ||||||
| MVI (Yes vs. No) | 0.006 | 3.962 | 1.389–11.302 | 0.010 | 0.005 | 2.169 | 1.025–4.591 | 0.043 |
| Satellite nodule (Yes vs. No) | 0.571 | 0.540 | ||||||
| Liver cirrhosis (Yes vs. No) | 0.071 | 0.031 | 3.306 | 1.134–9.636 | 0.028 | |||
| Ishak Fibrosis Score (≥4 vs. <4) | 0.076 | 0.071 | ||||||
| Transfusion (Yes vs. No) | 0.392 | 0.111 | ||||||
| BMI (≥25 vs. <25) | 0.981 | 0.130 | ||||||
| History of smoke (Yes vs. No) | 0.087 | 0.150 | ||||||
| Hypertension (Yes vs. No) | 0.190 | 0.143 | ||||||
| Diabetes (Yes vs. No) | 0.065 | 0.414 | ||||||
| Cardiovascular disease (Yes vs. No) | 0.815 | 0.895 | ||||||
| Alcohol abuse (Yes vs. No) | 0.081 | 0.787 | ||||||
| Antiviral therapy (ETV vs. TDF) | 0.068 | 3.056 | 1.015–9.196 | 0.047 | 0.046 | 2.57 | 1.264–5.228 | 0.009 |
AFP, Alpha Fetoprotein; ALB, Albumin; ALT, Alamine Aminotransfera; BCLC, Barcelona staging; CREA, Creatinine; ETV, Entecavir; HBeAg, Hepatitis B e Antigen; HBV, Hepatitis B Virus; HR, Hazard Ratio; ITT, Intention-to-treat; MVI, Microvascular Infiltration; TBIL, Total Bilirubin; TDF, Tenofovir Disoproxil Fumarate.
*
Multivariate Analysis: Multivariate analysis was based on the potential risk factors (P<0.1 in the univariate analysis).